The field station
About Meds BPC-157
An independent editorial readout of the published BPC-157 research — and a clear statement of what it is not.
What this site is
Meds BPC-157 is an independent editorial project that publishes summaries of the peer-reviewed research literature on BPC-157, the gastric pentadecapeptide. The site reads the published record — the angiogenesis mechanism, the cytoprotection and tissue-repair studies, the pharmacokinetic data, the three small human pilots, and the regulatory picture — and presents it as a cited, stratified readout. Our work is editorial commentary on publicly available science.
The design borrows the language of a research field station because that is the honest register for this body of work: a dense, mostly-preclinical literature that benefits from being layered — the established findings surfaced clearly, the mechanism beneath them, and the human-data gaps stated rather than hidden.
What this site is not
We are not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product, and nothing on this site is an offer to supply any substance. We do not prescribe, and we do not facilitate access to compounded medications.
The word "meds" in the domain name is editorial framing — a position this publisher takes toward the medicinal and regulatory literature, not a claim that the site offers medication, consultation, or any clinical service. Where we describe how compounded access works, on the BPC-157 legal status page, it is general regulatory information, not advice and not a route to a product.
How we handle the evidence
Every quantitative claim on the site — a dose, a percentage, a half-life, an effect — resolves to a numbered citation in the full reference list. We distinguish established preclinical findings from rodent-only signals, and we mark the human-evidence gaps plainly: as of 2025 reviews, only three small human pilot studies exist [11], and rigorous large-scale controlled trials are lacking.
We avoid product brand names, we do not give human dosing, and we do not present any pending or predicted regulatory outcome as a settled fact. When the record is uncertain, we say so. That discipline is the point of the site.